Abbott Laboratories (ABT) 42.56 $ABT
FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 11, 3:46PM CDT
Source: Takeda Pharmaceuticals Patients now have a third drug to treat their obesity. Today, Orexigen and Takeda Pharmaceuticals announced that the Food and Drug Administration approved its obesity drug Contrave . (The FDA made the same...
Abbott Laboratories (ABT) Declares Quarterly Dividend, Announces Share Buyback
at The Street - Thu Sep 11, 1:29PM CDT
Abbott Laboratories (ABT) declared its quarterly dividend of 22 cents a share Thursday, in line with its previous dividend.
FDA approves weight-loss drug Contrave
By MATTHEW PERRONE - AP - Thu Sep 11, 12:49PM CDT
WASHINGTON (AP) — U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.
Abbott Announces New $3 Billion Share Repurchase Program, Declares Dividend
PR Newswire - Thu Sep 11, 12:39PM CDT
Abbott's (NYSE: ABT) board of directors has approved a new share repurchase program and declared a quarterly common dividend.
Abbott Laboratories (ABT) Crosses Pivot Point Support at $42.67
Comtex SmarTrend(R) - Thu Sep 11, 10:36AM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today below their pivot of $42.86 and have already reached the first level of support at $42.67. Analysts will be watching for a cross of the next downside pivot targets of $42.44 and $42.02.
Abbott Once Again Named the Industry Leader for Responsible and Sustainable Business on the Dow Jones Sustainability Index (DJSI)
PR Newswire Europe - Thu Sep 11, 9:59AM CDT
- Abbott Achieved Top Industry Scores for Economic and Social Performance
FTC sues AbbVie, Teva over generic AndroGel
AP - Mon Sep 08, 1:53PM CDT
NEW YORK (AP) — The Federal Trade Commission is suing drugmakers AbbVie and Teva, saying they conspired to temporarily keep generic versions of AbbVie's low-testosterone drug AndroGel off the market.
Future Horizons and Growth Strategies in the Global Drugs of Abuse Testing Market 2014: Supplier Shares and Country Forecasts
M2 - Mon Sep 08, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wcgzf7/future_horizons) has announced the addition of the "Future Horizons and Growth Strategies in the Global Drugs of Abuse Testing Market 2014: Supplier Shares and Country Forecasts" report to their offering. This new 318-page report from contains 68 tables and provides analysis of the global drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers. 2014 Strategies for the Global Drugs of Abuse Testing Market is a unique study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study explores future trends in the U.S., five major European countries and Japan; and provides test volume and sales forecasts by country, market segment and individual assay. The report provides test volume and sales forecasts by country and market segment for the following assays: - Amphetamines - Antidepressants - Barbiturates - Benzodiazepines - Cannabinoids/Marijuana - Cocaine - LSD - Methadone - Methaqualone - Opiates - Phencyclidine (PCP) - Propoxphene Key Topics Covered: A. Major Drugs of Abuse B. Instrumentation Review C. Major In Vitro Diagnostic Technologies and Their Potential Applications D. Distribution Strategies for Decentralized Testing Markets E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges Companies Mentioned - Abbott Laboratories - AdnaGen - Beckman Coulter/Danaher - Biomedical Diagnostics - BioMerieux - Bio-Rad - Dako - DiaSorin - Eiken - Fujirebio - Instrumentation Laboratory - Kyowa Medex - Matritech/Alere - Ortho-Clinical Diagnostics - Roche - Siemens - Sysmex - Thermo Fisher - Tosoh - Wako - Wallac/PE For more information visit http://www.researchandmarkets.com/research/wc...e_horizons
New Abbott Technology May Uncover the Root of Critical Infections and Cut Health Care Costs
PR Newswire - Mon Sep 08, 8:24AM CDT
A new study suggests a pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately $2.2 million (EUR 1.5 million / £1.2 million).[1] The cost reductions are based on a health economic model from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study, presented today at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, D.C.
Why Baxter International Offers Great Reward for Minimal Risk
at The Street - Mon Sep 08, 5:00AM CDT
Wall Street is wrong to discount Baxter's value-creating potential.
Australia Peripheral Vascular & Cardiovascular Procedures Devices Market Outlook to 2020 New Report Available at MarketOptimizer.org
PRWeb - Sun Sep 07, 8:30PM CDT
Australia Peripheral Vascular Devices Market Outlook to 2020
Abbott Labs' FreeStyle Libre Flash Glucose Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:35PM CDT
Abbott Labs (ABT) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe.
Shares of ABT Up 9.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 05, 11:20AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 5 months, Abbott Laboratories has returned 9.85% as of today's recent price of $42.56.
The Zacks Analyst Blog Highlights: Google, AbbVie, Abbott Laboratories, Apple and Intel
PR Newswire - Fri Sep 05, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Google (Nasdaq:GOOGL-Free Report), AbbVie (NYSE:ABBV-Free Report), Abbott Laboratories (NYSE:ABT-Free Report), Apple Inc. (Nasdaq:AAPL-Free Report) and Intel (Nasdaq:INTC-Free Report).
Global Mobile Health and Fitness Sensor Market 2014-2018: Increased Health Awareness Sees Market Set to Grow at a CAGR of 40%
M2 - Fri Sep 05, 8:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mfnjth/global_mobile) has announced the addition of the "Global Mobile Health and Fitness Sensor Market 2014-2018" report to their offering. The Global Mobile Health and Fitness Sensor market to grow at a CAGR of 40.29 percent over the period 2013-2018. A sensor measures physical quantity and converts raw data into observable data, which are used by various industries. Mobile health and fitness sensors are used in health and fitness devices to measure various body parameters. Rapid and continuous development in sensing technology can assist in regular patient monitoring. Going forward, the use of mobile health and fitness sensors in consumer healthcare is expected to boost the Global Mobile Health and Fitness Sensor market. The Global Mobile Health and Fitness Sensor market covers the present scenario and the growth prospects for the period 2014-2018. To calculate market size, the report takes into account the unit shipments of health and fitness sensors used in wearable, implantable, and mobile health and fitness devices. With growing demand from consumers, vendors have started developing multi-functional sensors that can be used to measure different body activities with a single device. The decreasing size of sensors led to a concomitant increase in the demand for implantable sensors. This demand is expected to increase during the forecast period of 2013-2018. According to the report, increased health awareness is a major driver for the Global Mobile Health and Fitness Sensor market. Aging populations and an increased incidence of diseases coupled with higher healthcare costs are some of the concerns and people are becoming increasingly health conscious and are constantly monitoring their body condition to keep fit. Further, the report states that lack of standardization among health and fitness devices remains a major challenge to the growth of the Global Mobile Health and Fitness Sensor market. Key Vendors - Abbott Laboratories - Acute Technology - Bayer HealthCare - F. Hoffmann-La Roche - Fujitsu - GE Healthcare - Honeywell International - LifeScan - Medtronic - OMRON - RF Technologies Other Prominent Vendors - Adidas - AgaMatrix - Analog Devices - Asahi Kasei Microdevices - Bosch Healthcare - Cardiocomm Solutions - Casio - Cellnovo - ChoiceMmed - Covidien - EM Microelectronic - Jawbone - Lifecomm - Philips - Qualcomm - ST Microelectronics - Texas Instruments - Zensorium Market Drivers/Challenges/Trends - Increased Health Awareness - Lack of Standardization - Rapid Growth in Combo Sensors Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by End-users - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/mf...bal_mobile
Abbott Labs' Weakness in Devices Hurts Long-Term Growth Potential
at The Street - Fri Sep 05, 5:00AM CDT
There's no compelling reason to buy this stock above $40.
Google's Calico in $500M Joint Venture with AbbVie - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:38PM CDT
Calico, Google's (GOOGL) year-old health startup is collaborating with biotechnology drugmaker, AbbVie, a spin-off from Abbott Laboratories (ABT), for a joint venture to formulate treatments for cancer and Alzheimer's.
Global Companion Diagnostic Technologies Market Opportunities and Forecasts 2013 - 2020
M2 - Thu Sep 04, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qr68q/global_companion) has announced the addition of the "Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global companion diagnostic market is expected to reach $3.5 billion by 2020, and it would grow at a CAGR of 20% from 2014 to 2020 Companion diagnostics market by indication is segmented into oncology, cardiovascular, CNS, autoimmune & inflammation, virology and others. Presently, majority of the companion diagnostics have been developed for cancer and thus, it is the major revenue generating segment in the overall CD indication market. Companion diagnostics have been developed for breast cancer, lung cancer, colorectal cancer, gastric cancer and melanomas. Companion diagnostics for breast cancer is the highest revenue generator mainly because there has been an increase in the incidences of breast cancer and many companion diagnostics have been developed for detection of the HER/neu biomarker for breast cancer. As of now, companion diagnostics for cardiovascular conditions, central nervous system conditions , inflammation and autoimmune diseases and viral diseases are very few, with a majority still in development stage; however, as more and more biomarkers are being discovered, there would be an increase in development of new companion diagnostics. Companion diagnostics market by technology is segmented into immmunohistochemistry and molecular diagnostics. Molecular diagnostics has been the most favored technology and it is expected that next generation sequencing and real-time PCR would drive the growth of this market owing to recent advancements in these technologies. KEY DELIVERABLES MARKET BY INDICATIONS - Oncology - Cardiovascular - Central Nervous System - Auto immune & Inflammation - Virology - Others MARKET BY TECHNOLOGY - Immunohistochemistry - Molecular diagnostics - In situ Hybridization - FISH - CISH - Real time PCR - Gene Sequencing COMPANY PROFILES - Abbott Laboratories - bioMerieux - Dako (Agilent Technologies) - Leica Microsystems - Life Technologies - Myriad Genetics - Qiagen - Resonance Health Ltd - Roche - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/3q..._companion
FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 11, 3:46PM CDT
Source: Takeda Pharmaceuticals Patients now have a third drug to treat their obesity. Today, Orexigen and Takeda Pharmaceuticals announced that the Food and Drug Administration approved its obesity drug Contrave . (The FDA made the same...
Abbott Laboratories (ABT) Declares Quarterly Dividend, Announces Share Buyback
at The Street - Thu Sep 11, 1:29PM CDT
Abbott Laboratories (ABT) declared its quarterly dividend of 22 cents a share Thursday, in line with its previous dividend.
FDA approves weight-loss drug Contrave
By MATTHEW PERRONE - AP - Thu Sep 11, 12:49PM CDT
WASHINGTON (AP) — U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.
Abbott Announces New $3 Billion Share Repurchase Program, Declares Dividend
PR Newswire - Thu Sep 11, 12:39PM CDT
Abbott's (NYSE: ABT) board of directors has approved a new share repurchase program and declared a quarterly common dividend.
Abbott Laboratories (ABT) Crosses Pivot Point Support at $42.67
Comtex SmarTrend(R) - Thu Sep 11, 10:36AM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today below their pivot of $42.86 and have already reached the first level of support at $42.67. Analysts will be watching for a cross of the next downside pivot targets of $42.44 and $42.02.
Abbott Once Again Named the Industry Leader for Responsible and Sustainable Business on the Dow Jones Sustainability Index (DJSI)
PR Newswire Europe - Thu Sep 11, 9:59AM CDT
- Abbott Achieved Top Industry Scores for Economic and Social Performance
FTC sues AbbVie, Teva over generic AndroGel
AP - Mon Sep 08, 1:53PM CDT
NEW YORK (AP) — The Federal Trade Commission is suing drugmakers AbbVie and Teva, saying they conspired to temporarily keep generic versions of AbbVie's low-testosterone drug AndroGel off the market.
Future Horizons and Growth Strategies in the Global Drugs of Abuse Testing Market 2014: Supplier Shares and Country Forecasts
M2 - Mon Sep 08, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wcgzf7/future_horizons) has announced the addition of the "Future Horizons and Growth Strategies in the Global Drugs of Abuse Testing Market 2014: Supplier Shares and Country Forecasts" report to their offering. This new 318-page report from contains 68 tables and provides analysis of the global drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers. 2014 Strategies for the Global Drugs of Abuse Testing Market is a unique study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study explores future trends in the U.S., five major European countries and Japan; and provides test volume and sales forecasts by country, market segment and individual assay. The report provides test volume and sales forecasts by country and market segment for the following assays: - Amphetamines - Antidepressants - Barbiturates - Benzodiazepines - Cannabinoids/Marijuana - Cocaine - LSD - Methadone - Methaqualone - Opiates - Phencyclidine (PCP) - Propoxphene Key Topics Covered: A. Major Drugs of Abuse B. Instrumentation Review C. Major In Vitro Diagnostic Technologies and Their Potential Applications D. Distribution Strategies for Decentralized Testing Markets E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges Companies Mentioned - Abbott Laboratories - AdnaGen - Beckman Coulter/Danaher - Biomedical Diagnostics - BioMerieux - Bio-Rad - Dako - DiaSorin - Eiken - Fujirebio - Instrumentation Laboratory - Kyowa Medex - Matritech/Alere - Ortho-Clinical Diagnostics - Roche - Siemens - Sysmex - Thermo Fisher - Tosoh - Wako - Wallac/PE For more information visit http://www.researchandmarkets.com/research/wc...e_horizons
New Abbott Technology May Uncover the Root of Critical Infections and Cut Health Care Costs
PR Newswire - Mon Sep 08, 8:24AM CDT
A new study suggests a pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately $2.2 million (EUR 1.5 million / £1.2 million).[1] The cost reductions are based on a health economic model from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study, presented today at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, D.C.
Why Baxter International Offers Great Reward for Minimal Risk
at The Street - Mon Sep 08, 5:00AM CDT
Wall Street is wrong to discount Baxter's value-creating potential.
Australia Peripheral Vascular & Cardiovascular Procedures Devices Market Outlook to 2020 New Report Available at MarketOptimizer.org
PRWeb - Sun Sep 07, 8:30PM CDT
Australia Peripheral Vascular Devices Market Outlook to 2020
Abbott Labs' FreeStyle Libre Flash Glucose Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:35PM CDT
Abbott Labs (ABT) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe.
Shares of ABT Up 9.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 05, 11:20AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 5 months, Abbott Laboratories has returned 9.85% as of today's recent price of $42.56.
The Zacks Analyst Blog Highlights: Google, AbbVie, Abbott Laboratories, Apple and Intel
PR Newswire - Fri Sep 05, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Google (Nasdaq:GOOGL-Free Report), AbbVie (NYSE:ABBV-Free Report), Abbott Laboratories (NYSE:ABT-Free Report), Apple Inc. (Nasdaq:AAPL-Free Report) and Intel (Nasdaq:INTC-Free Report).
Global Mobile Health and Fitness Sensor Market 2014-2018: Increased Health Awareness Sees Market Set to Grow at a CAGR of 40%
M2 - Fri Sep 05, 8:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mfnjth/global_mobile) has announced the addition of the "Global Mobile Health and Fitness Sensor Market 2014-2018" report to their offering. The Global Mobile Health and Fitness Sensor market to grow at a CAGR of 40.29 percent over the period 2013-2018. A sensor measures physical quantity and converts raw data into observable data, which are used by various industries. Mobile health and fitness sensors are used in health and fitness devices to measure various body parameters. Rapid and continuous development in sensing technology can assist in regular patient monitoring. Going forward, the use of mobile health and fitness sensors in consumer healthcare is expected to boost the Global Mobile Health and Fitness Sensor market. The Global Mobile Health and Fitness Sensor market covers the present scenario and the growth prospects for the period 2014-2018. To calculate market size, the report takes into account the unit shipments of health and fitness sensors used in wearable, implantable, and mobile health and fitness devices. With growing demand from consumers, vendors have started developing multi-functional sensors that can be used to measure different body activities with a single device. The decreasing size of sensors led to a concomitant increase in the demand for implantable sensors. This demand is expected to increase during the forecast period of 2013-2018. According to the report, increased health awareness is a major driver for the Global Mobile Health and Fitness Sensor market. Aging populations and an increased incidence of diseases coupled with higher healthcare costs are some of the concerns and people are becoming increasingly health conscious and are constantly monitoring their body condition to keep fit. Further, the report states that lack of standardization among health and fitness devices remains a major challenge to the growth of the Global Mobile Health and Fitness Sensor market. Key Vendors - Abbott Laboratories - Acute Technology - Bayer HealthCare - F. Hoffmann-La Roche - Fujitsu - GE Healthcare - Honeywell International - LifeScan - Medtronic - OMRON - RF Technologies Other Prominent Vendors - Adidas - AgaMatrix - Analog Devices - Asahi Kasei Microdevices - Bosch Healthcare - Cardiocomm Solutions - Casio - Cellnovo - ChoiceMmed - Covidien - EM Microelectronic - Jawbone - Lifecomm - Philips - Qualcomm - ST Microelectronics - Texas Instruments - Zensorium Market Drivers/Challenges/Trends - Increased Health Awareness - Lack of Standardization - Rapid Growth in Combo Sensors Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by End-users - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/mf...bal_mobile
Abbott Labs' Weakness in Devices Hurts Long-Term Growth Potential
at The Street - Fri Sep 05, 5:00AM CDT
There's no compelling reason to buy this stock above $40.
Google's Calico in $500M Joint Venture with AbbVie - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:38PM CDT
Calico, Google's (GOOGL) year-old health startup is collaborating with biotechnology drugmaker, AbbVie, a spin-off from Abbott Laboratories (ABT), for a joint venture to formulate treatments for cancer and Alzheimer's.
Global Companion Diagnostic Technologies Market Opportunities and Forecasts 2013 - 2020
M2 - Thu Sep 04, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qr68q/global_companion) has announced the addition of the "Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global companion diagnostic market is expected to reach $3.5 billion by 2020, and it would grow at a CAGR of 20% from 2014 to 2020 Companion diagnostics market by indication is segmented into oncology, cardiovascular, CNS, autoimmune & inflammation, virology and others. Presently, majority of the companion diagnostics have been developed for cancer and thus, it is the major revenue generating segment in the overall CD indication market. Companion diagnostics have been developed for breast cancer, lung cancer, colorectal cancer, gastric cancer and melanomas. Companion diagnostics for breast cancer is the highest revenue generator mainly because there has been an increase in the incidences of breast cancer and many companion diagnostics have been developed for detection of the HER/neu biomarker for breast cancer. As of now, companion diagnostics for cardiovascular conditions, central nervous system conditions , inflammation and autoimmune diseases and viral diseases are very few, with a majority still in development stage; however, as more and more biomarkers are being discovered, there would be an increase in development of new companion diagnostics. Companion diagnostics market by technology is segmented into immmunohistochemistry and molecular diagnostics. Molecular diagnostics has been the most favored technology and it is expected that next generation sequencing and real-time PCR would drive the growth of this market owing to recent advancements in these technologies. KEY DELIVERABLES MARKET BY INDICATIONS - Oncology - Cardiovascular - Central Nervous System - Auto immune & Inflammation - Virology - Others MARKET BY TECHNOLOGY - Immunohistochemistry - Molecular diagnostics - In situ Hybridization - FISH - CISH - Real time PCR - Gene Sequencing COMPANY PROFILES - Abbott Laboratories - bioMerieux - Dako (Agilent Technologies) - Leica Microsystems - Life Technologies - Myriad Genetics - Qiagen - Resonance Health Ltd - Roche - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/3q..._companion
